StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Leqvio (inclisiran by Quarter

Leqvio (inclisiran — 2 times/year injectable siRNA for lowering LDL-C cholesterol) ($M)

QuarterlyAnnual

Novartis Leqvio (inclisiran: $506M in Q3 2026, up 64.3% from a year earlier. That is the highest of the 22 quarters on record here.

Latest, Q3 2026
506
Period ended Sep 30, 2026
Change on a year earlier
+64.3%
308 in Q3 2025
History
22 quarters
Since Q1 2021
Sources
18
Documents cited below

Where the Q3 2026 figure comes from

“|| Leqvio | 506 | 308 | 64 | 63”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLeqvio (inclisiran — 2 times/year injectable siRNA for lowering LDL-C cholesterol) ($M)Year on yearSource
Q3 2026Sep 30, 2026506+64.3%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026480+61.1%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026452+75.9%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025335+50.2%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 2025308+55.6%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 2025298+63.7%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2025Mar 31, 2025257+70.2%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 2024223+81.3%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 2024198+120.0%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 2024182+133.3%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2024Mar 31, 2024151+135.9%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2023Dec 31, 2023123+192.9%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2023Sep 30, 202390+164.7%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2023Jun 30, 202378+254.5%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2023Mar 31, 202364+357.1%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2022Dec 31, 202242+950.0%Novartis Form 6-K (0001370368-24-000007) ↗

Breakdown

What makes up leqvio (inclisiran

Cite this data

StockData. (2026). Novartis Leqvio (inclisiran ($M), quarterly Q1 2021–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-leqvio

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.